A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed limited stage small cell lung cancer (SCLC)

- Evidence of disease by CT scan of the chest

- Measurable or evaluable disease outside of area of prior surgical resection

- No malignant pericardial or pleural effusions (cytologically positive effusions or
exudative effusions not attributable to other etiologies)

- No CNS disease by chest CT scan or MRI

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- Zubrod 0-1

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic

- Not specified

Renal

- Creatinine no greater than upper limit of normal OR

- Creatinine clearance at least 60 mL/min

Other

- No prior hypersensitivity or contraindication to monoclonal antibody 11D10
anti-idiotype vaccine (TriAb), monoclonal antibody GD2 anti-idiotype vaccine
(TriGem), or aluminum hydroxide

- No known sensitivity to rodent proteins (i.e., anti-OKT-3, ONCOSCINT scan)

- No grade 1 or greater symptomatic sensory neuropathy

- No other malignancy except adequately treated basal cell or squamous cell skin
cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer in
complete remission, or any other cancer for which patient has been disease free for 5
years

- If significant clinical hearing loss already present, must accept risk of further
hearing loss

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No prior biologic therapy for SCLC

- No prior TriAb or TriGem

- No prior murine antibodies

- No prior mouse proteins

- At least 30 days since prior immunotherapy

- At least 30 days since any prior immunization

Chemotherapy

- No prior systemic chemotherapy for SCLC

- No concurrent cyclophosphamide or methotrexate

Endocrine therapy

- At least 30 days since prior systemic corticosteroids

- No concurrent systemic corticosteroids (except as an antiemetic)

Radiotherapy

- No prior radiotherapy to the thorax or neck region

- No concurrent intensity modulated radiotherapy

Surgery

- See Disease Characteristics

- At least 2 weeks since prior thoracic or other major surgery and recovered

Other

- At least 30 days since prior investigational agents or devices

- No other concurrent investigational agents

- No other concurrent immunosuppressants (e.g., cyclosporine)

- No concurrent chronic systemic antihistamines

- No concurrent amifostine